Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025

LONDON, July 10, 2015 /PRNewswire/ --

Clinical Trials - Discover Commercial Potentials of Outsourced Drug Testing, Benefiting Your Authority
What does the future hold for pharmaceutical clinical research providers? Visiongain's new study gives you multilevel revenue forecasts from 2015 to 2025. It explains trends, opportunities and selling prospects for that drug development and testing.

Our report predicts sales at overall world market, submarket and national level. There you find the most promising and lucrative parts of clinical trial outsourcing, helping your research and analysis. That way stay ahead, saving time and hassle, also benefiting your influence.

Clinical research organisations (CROs) and drug companies using them will benefit from expansion of that industry and market. Those technologies and outsourced services hold rising importance in pharmaceutical R&D. See why and how, finding the gains possible.

Read on, then, to explore those contracting services for benefiting medicine. Find what influences that market and see predicted revenue.

Forecasts and other analyses to help you stay ahead in knowledge
Why struggle to find information or miss data you need on clinical outsourcing and off-shoring? Instead reduce worry there, helping your searches, proposals and presentations.

So in our work discover where the money lies, and best places for business expansion. In that study you explore revenue forecasting to 2025, results and other statistics, growth rates, leading companies and market shares.

You also assess qualitative analysis (SWOT and STEP), news, business progress, outlooks and developmental needs - pharma R&D trends and demands. You find expected gains.

There you get 78 tables, 65 charts and interviews with three companies. The clinical testing market will increase its revenues from 2015 to 2025, achieving strong sales expansion. Our survey's purpose is to explain those needs, opportunities and potentials.

That way you hear what's happening, helping you stay ahead. And the following sections explain how our new investigation benefits your work.

To see a report overview please email Sara Peerun on [email protected]

Predictions for the world market and submarkets - what's possible?
Along with revenue prediction for the overall world market, you see individual forecasts to 2025 for nine submarkets:

• Early phase services
• Late phase services
• Other related services (grouped).

You also get individual forecasts for contract clinical services at world level by therapeutic area:

• Cancer (oncology)
• Cardiovascular diseases
• CNS disorders
• Metabolic conditions
• Infective diseases
• Other treatment testing needs (grouped prediction).

There gain advantages by understanding trends, needs, opportunities and challenges. Our investigation shows what will stimulate and restrain CROs, helping you stay ahead in knowledge. That way, benefit your business and reputation for commercial insight.

Our work also divides its overall world sales forecast into geographical markets.

Clinical trial outsourcing - what prospects for research in leading regions and countries?
Demands worldwide from drug developers influence service providers from 2015, especially extending clinical research in developing countries. Many opportunities exist for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

Our new study gives individual forecasts to 2025 for 12 national markets and a regional group, predicting overall revenues:

• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5 countries)
• Central and Eastern Europe (CEE, grouped forecast of that region)
• Brazil, Russia, India and China (BRIC nations) and South Korea.

There discover progress and commercial outlooks. You assess the industry's future - hear about

To see a report overview please email Sara Peerun on [email protected]

Forces, policies and changes from 2015 affecting clinical testing services
Our report discusses regulations, changes and other influences shaping that industry and market from 2015:

• Future of outsourced phase I, II and III trials and post-marketing studies, inc. pharmacovigilance
• Demand from pharmaceutical companies for drug safety and efficacy testing, including new trial designs
• Regulations (e.g. FDA, EMA, MHLW) - policies, guidelines, ethics, changes and what they mean for that contracting industry and trial sponsors
• Number of registered studies - present and historical trends
• Challenges in developed and developing countries - improving systems and results
• Adaptive trial designs for medicines and focus on late-stage R&D pipeline candidates
• Patient recruitment and retention - overcoming challenges.

The survey also discusses these aspects of that medical research and development:

• Social media as tools for engaging patients in trials - communications technology
• Operational improvements for more-efficient trials - inc. electronic health records, IT advances in medical data capture, databases and cloud computing
• Risk-sharing partnerships and agreements between CROs and pharma clients
• CRO consolidation, specialisation and globalisation, including mergers, acquisitions and alliances, including supplier networks
• Biological drug testing, inc. orphan drugs, biosimilars and emerging biologics - extending applications and ranges of therapeutic research
• Biomarkers in drug development - improving the efficiency and precision of testing and data analysis, also with cost savings.

That way you find what stimulates and restrains organisations providing those testing operations, affecting their results and those of clients.

So see what the future holds. You investigate social, technological, economic and political questions, exploring companies, competition and business outlooks. Avoid falling behind.

Leading companies and 2019 market value - what revenue possible?
Our study predicts the overall world market for clinical trial services will reach $32bn in 2019, with high, fast-expanding revenues to 2025. From 2015 that outsourcing sector holds great potential for investments, developments and revenue growth. You see how it will progress.

That work profiles 14 leading CROs, ranging from global market players to regional medium-sized companies. The competitive intelligence includes these firms:

• Quintiles
• Laboratory Corporation of America (LabCorp)
• Pharmaceutical Product Development (PPD)
• Parexel International
• ICON
• inVentiv Health
• PRA Health Sciences
• Charles River Laboratories.

Also you discover interviews with three companies: Quotient Clinical, MPI Research and The Clinical Trial Company. How do CROs remain competitive? What are the secrets to their industry's progress? Find what influences clinical research contractors' success.

From 2015 to 2025, many opportunities will arise for pharma contract research organisations. Stay ahead there. Our work shows technological and commercial possibilities. It explains how professionals such as you - and their organisations - can gain.

Way Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025 helps
In these five main ways, our new study helps you gain in recognition for insight, also saving time and benefiting your authority:
• Revenues for pharma clinical outsourcing, to 2025, at world level and for 9 submarkets - discover prospects for services, testing needs and spending trends
• Forecasts, to 2025, for 12 countries in the Americas, Europe and Asia - explore developed and developing national markets for demand and predicted revenues
• Prospects for established organisations, rising companies and new entrants - assess firms' portfolios, results, technologies, strategies and outlooks for success
• Analysis of what stimulates and restrains clinical testing providers - investigate challenges, strengths and competition affecting those organisations' results
• Interviews with that industry - discover what other experts in that field think, say and do, helping you stay ahead in technological, medical and commercial knowledge.

That report, by visiongain's in-house analysts in the UK, gives knowledge to benefit your work, saving you hassle and time. You gain data leading companies depend on.

Information found nowhere else, helping your searches, analyses, plans and presentations
That work gives independent analysis. There you get competitive intelligence found only in our report, discovering the CRO industry's most promising opportunities and financial prospects.

An off-the-shelf report can't answer every question, though our work explains that industry's structures, outlooks and potentials in depth and breadth. That's our purpose, helping you stay ahead and succeed.

With our new study you're less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, saving time, helping your business and gaining in recognition for market insight.

Trying our report now lets you discover what's possible, seeing how you can gain
Stay ahead in data. Our new investigation is for everyone assessing pharmaceutical R&D operations. For clinical testing services you explore trends, needs, opportunities and revenue potentials.

So discover what's possible and avoid missing out. Please get that report here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://goo.gl/e4gUAz

Companies and Other Organisations Mentioned in the Report
3C Alliance
Actavis
Adamas Pharmaceuticals
Adheris (an InVentiv Health company)
Administration of Science, Technology and Training (ASST) [Vietnam]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agenzia Italiana del Farmaco (AIFA) [Italy]
Agilent Technologies
Agility Clinical
AKESOgen
Akos
Allscripts
Amgen
Aptiv Solutions (now part of ICON plc)
Aptuit
ASAN Medical Center
Assent Consulting
Associação Brasileira de CROs (Abracro)
Association for the Accreditation of Human Research Protection Programs (AAHRPP)
Association of Clinical Trial Organisations (ACTO) [Russia]
Astellas Pharma
Avista Capital Partners
Baxter International
Bayer
BeijingWits Medical Consulting (part of ICON)
Ben's Friends
Berry Consultants
BioBay
BioClinica
BioDuro (part of PPD)
BioDuro Biologics
Biogen Idec
Biomedical Systems
BioTrak
Bioxydyn
BML
Boehringer Ingelheim
Bridgepoint Development Capital
Bristol-Myers Squibb
Caprion
Catalent
Catalina Health (part of InVentiv Health)
Celerion
Center for Biologics Evaluation and Research (CBER) [US]
CenterWatch
Central Drugs Standard Control Organization (CDSCO) [India]
Center for Drug Evaluation (CDE)
Charles River Laboratories
China Food and Drug Administration (CFDA)
Chinese Ministry of Commerce
ClinForce
Clinical Trial Support
Clinigene International
Clinipace Worldwide
ClinStar
CMIC Holdings
CMIC (Beijing) Co
CNS Healthcare
CNS Vital Signs
Cogtest (part of The Cognition Group)
Corex Pharmaceutical
Council for International Organizations of Medical Sciences (CIOMS)
CRI Lifetree (part of PRA Health Sciences)
Cromos Pharma
CROMSOURCE
Cross Country Healthcare Inc
Czura Thornton
Dako (part of Agilent Technologies)
Department of Health [UK]
Department of Health and Human Services [US]
Drug Controller General of India (DCGI)
Duke Clinical Research Institute
EF Education First
Eisai
Ekam Imaging
Eli Lilly
EPS Corporation (now EPS Holdings, Inc.)
EPS Holdings, Inc.
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Parliament
Firecrest Clinical (part of ICON)
Forest Pharmaceuticals
Food and Drug Administration (US FDA)
Frontage Laboratories
GCP ClinPlus
GE Healthcare
Genstar Capital
Global CNS Research
Global Research Services (GRS)
Główny Urząd Statystyczny (Polish Central Statistical Office)
GSK
Harlan Laboratories (part of Huntingdon Life Sciences)
Hellman & Friedman
Hisun Pharmaceuticals
Hospital Italiano de Buenos Aires
Huntingdon Life Sciences
i3 Research (part of inVentiv Health)
ICON
ImageIQ
ImmuneHealth
INC Research
Infociencia (part of RPS)
Innovative Medicines Initiative (IMI)
Inspire
Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
Integrium
International Cancer Genome Consortium
International Conference of Harmonisation (ICH)
inVentiv Health
J&J
Janssen Pharmaceuticals (a subsidiary of J&J)
Japan Pharmaceutical Manufacturers Association (JPMA)
Jasper Clinical Research and Development Inc.
Java Clinical
JCL Bioassay Corporation (part of CMIC Holdings)
Julphar
Kendle (part of INC Research)
Kester Capital
Kforce
Kforce Clinical Research (KCR, part of inVentiv Health)
Kinship Technologies (part of PRA Health Sciences)
KKR
Korea Drug Development Fund (KDDF)
Korea Food and Drug Administration (KFDA)
Korea National Enterprise for Clinical Trials (KoNECT)
Kun Tuo (part of Quintiles)
L'Agence Nationale de Sécurité du Medicament (L'ANSM) [France]
Laboratory Corporation of America (LabCorp)
Les Entreprises du Médicament (LEEM)
LSK Global
MAB Discovery
Malaysian Biotechnology Corporation
Massachusetts General Hospital
Maximax Pharmaceutical Research
MDS Pharma Services (part of INC Research)
MedAvante
Medaxial
Medelis
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Medidata Solutions
MediMedia Pharma Solutions (now part of ICON plc)
Medipal Holdings
Medivation
MEK Consulting (part of INC Research)
Merck & Co.
Merck BioVentures
Merck KGaA
Metabolon
MetricStream
Ministry of Health, Labor and Welfare (MHLW, Japan)
Ministry of Public Health [Russia]
Mitsubishi Gas Chemical Company, Inc.
Molecular NeuroImaging
MorphoSys
MPI Research
MRM Proteomics
Myriad Genetics
Mytrus
National Cancer Institute (NCI) [US]
National Institute for Health and Care Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
National Taiwan University Hospital (NTUH)
Nautic Partners
NeuroImage
NextGen Sciences
Nexus Oncology, an Ockham Company (formerly Nexus Oncology)
NHS Research Scotland (NRS)
Novartis
Novotech
Ockham
OCT
Omnicare
Oncobiologics
Ontario Teachers' Pension Plan
Oxford Cancer Biomarkers
Oxford Gene Technology (OGT)
Oxford Outcomes (part of ICON)
Pacific Biomarkers
Paragon Biomedical (part of Clinipace Worldwide)
Paramax International (part of RPS)
Parexel International
PatientsLikeMe
Perceptive Informatics (part of Parexel)
PFC Pharma Focus (part of Clinipace Worldwide)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
PharmaNet Development Group (part of inVentiv Health)
Pharmaron
PPD
PRA International
Prana Biotechnology
PriceSpective (part of ICON)
Prodia Clinical Laboratory
Proteome Sciences
ProTrials Research
PSR Orphan Experts
Psychmed (part of The Cognition Group)
QED Clinical Services
Quintiles
Quotient Clinical
RCT Logic
Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
ReSearch Pharmaceutical Services (RPS, part of PRA International)
Roche
Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
Samsung
SAS
Seoul National University Hospital Clinical Trial Center
Shanghai Clinical Research Center
ShangPharma
Shire
State Food and Drug Administration (SFDA) [China] (now CFDA)
Syngene International
Sugi Medical Co (part of CMIC)
Taijitu Biologics
Targos Molecular Pathology
Tessella
The Carlyle Group
The Clinical Trial Company
The Cognition Group
Theorem Clinical Research
Theradex Systems
Therapeutic Goods Administration (TGA) [Australia]
Therapharm Recherches (part of RPS)
Thomas H. Lee Partners
Tigermed Consulting
Timaq Medical Imaging (part of ICON)
Trident Clinical Research (part of INC Research)
UCB
University of Manchester
Veeda Clinical Research
Veeva Systems
Vigiun (part of Chiltern International)
VirtualScopics
Warburg Pincus
West Coast Clinical Trials (WCCT)
World Health Organization (WHO)
World Heart Foundation
Worldwide Clinical Research
WuXi AppTec
WuXi PharmaTech
Yungjin Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd

SOURCE Visiongain